# Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer

> **NCT01359397** · PHASE2 · UNKNOWN · sponsor: **The Netherlands Cancer Institute**

## Conditions studied

- Metastatic Gastric Cancer
- Adenocarcinoma of the Gastro-oesophageal Junction

## Interventions

- **DRUG:** Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab
- **DRUG:** Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab

## Key facts

- **NCT ID:** NCT01359397
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2015-05
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359397, "Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01359397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*